Use of intrathecal baclofen in a child with spastic paraparesis related to human immunodeficiency virus infection: A case report.
This case report describes a 2-year treatment course of a 6-year-old with spastic paraparesis due to human immunodeficiency virus (HIV) encephalopathy. She continued to develop worsening musculoskeletal problems and a decline in mobility despite aggressive antispasticity interventions. In addition to meeting the usual clinical criteria for treatment with continuous intrathecal baclofen (ITB), she was believed to be an appropriate candidate for ITB because of adequate treatment of her HIV infection and associated overall low risk of mortality. For over 12 months, she has been successfully treated with ITB and has not developed any complications related to her HIV infection. To my knowledge, this is the first reported successful treatment of spasticity with ITB in a patient with stable HIV infection.
Kolaski
Kat
K
Department of Orthopaedic Surgery, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA. kkolaski@wfubmc.edu
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D001418:Baclofen / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D007278:Injections, Spinal; D009125:Muscle Relaxants, Central / Q000008:administration & dosage / Q000627:therapeutic use*; D020336:Paraparesis, Spastic / Q000188:drug therapy* / Q000209:etiology*
D009125:Muscle Relaxants, Central; D001418:Baclofen